Triple-negative breast cancer, characterized by the lack of expression of three receptors, namely estrogen, progesterone, and human epidermal growth factor receptor 2 (HER-2) protein, cannot benefit from the hormonal therapies and drugs that target these receptors. Patients often become resistant to both the treatment options of surgery and chemotherapy. A team of researchers has recently tested a novel approach of combining an experimental drug N(G)-Monomethyl-L-Arginine (L-NMMA) with the standard chemotherapeutic drug, docetaxel.
Triple-negative breast cancer is mainly treated using lumpectomy, mastectomy, radiation, or chemotherapy. However, developing resistance to these treatments and reoccurrence of the cancer are the major challenges faced while treating cancer patients. Therefore, researchers have proposed a drug combination to be used in addition to the existing drugs, which…
